No formal hypothesis tests will be performed for the primary endpoint. The statistical analysis will be mainly descriptive and the number of adverse events attributable to felodipine will be summarised by dose for each cohort.

The two exploratory endpoints will be analysed as follows:

- The changes in clinical measurements of HD between baseline (week 0) and week 62 will be summarised and tested for significant change via a t-test.
- The change in brain MRI between baseline (week 0) and week 62 will be summarised for a range of volumetric measures.

No formal subgroup analyses will be performed in this trial.

A full statistical analysis plan has been produced for the final analysis.